Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population Inclusion and Exclusion Criteria
2.2. Study Protocol
2.3. Statistical Analysis
3. Results
3.1. Demographic Data
3.2. Biomarkers’ Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Rebolj, M.; Rimmer, J.; Denton, K.; Tidy, J.; Mathews, C.; Ellis, K.; Smith, J.; Evans, C.; Giles, T.; Frew, V.; et al. Primary cervical screening with high risk human papillomavirus testing: Observational study. BMJ 2019, 364, l240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ronco, G.; Dillner, J.; Elfström, K.M.; Tunesi, S.; Snijders, P.J.; Arbyn, M.; Kitchener, H.; Segnan, N.; Gilham, C.; Giorgi-Rossi, P.; et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 2014, 383, 524–532. [Google Scholar] [CrossRef]
- Hurtado-Salgado, E.; Cárdenas-Cárdenas, L.; Salmerón, J.; Luna-Gordillo, R.; Ortiz-Panozo, E.; Allen-Leigh, B.; Saavedra-Lara, N.; Franco, E.L.; Lazcano-Ponce, E. Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. Int. J. Cancer 2021, 150, 1422–1430. [Google Scholar] [CrossRef] [PubMed]
- Bray, F.; Loos, A.H.; McCarron, P.; Weiderpass, E.; Arbyn, M.; Moller, H.; Hakama, M.; Parkin, D.M. Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol. Biomark. Prev. 2005, 14, 677–686. [Google Scholar] [CrossRef] [Green Version]
- Quinn, M.; Babb, P.; Jones, J.; Allen, E. Effect of screening on incidence of and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics. BMJ 1999, 318, 904–908. [Google Scholar] [CrossRef] [Green Version]
- Canfell, K.; Smith, M.; Saville, M.; Arbyn, M. HPV screening for cervical cancer is reaching maturity. BMJ 2022, 377, o1303. [Google Scholar] [CrossRef]
- Canfell, K.; Sitas, F.; Beral, V. Cervical cancer in Australia and the United Kingdom: Comparison of screening policy and uptake, and cancer incidence and mortality. Med. J. Aust. 2006, 185, 482–486. [Google Scholar] [CrossRef]
- Sasieni, P.; Adams, J.; Cuzick, J. Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. Br. J. Cancer 2003, 89, 88–93. [Google Scholar] [CrossRef] [Green Version]
- Nuovo, J.; Melnikow, J.; Willan, A.R.; Chan, B.K. Treatment outcomes for squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 2000, 68, 25–33. [Google Scholar] [CrossRef]
- Kyrgiou, M.; Tsoumpou, I.; Vrekoussis, T.; Martin-Hirsch, P.; Arbyn, M.; Prendiville, W.; Mitrou, S.; Koliopoulos, G.; Dalkalitsis, N.; Stamatopoulos, P.; et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev. 2006, 32, 516–523. [Google Scholar] [CrossRef]
- Soutter, W.P.; de Barros Lopes, A.; Fletcher, A.; Monaghan, J.M.; Duncan, I.D.; Paraskevaidis, E.; Kitchener, H.C. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997, 349, 978–980. [Google Scholar] [CrossRef]
- Kalliala, I.; Anttila, A.; Pukkala, E.; Nieminen, P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: Retrospective cohort study. BMJ 2005, 331, 1183–1185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin-Hirsch, P.P.; Paraskevaidis, E.; Bryant, A.; Dickinson, H.O. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2013, 2013, Cd001318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalliala, I.; Athanasiou, A.; Veroniki, A.A.; Salanti, G.; Efthimiou, O.; Raftis, N.; Bowden, S.; Paraskevaidi, M.; Aro, K.; Arbyn, M.; et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: A systematic review and meta-analysis of the literature. Ann. Oncol. 2020, 31, 213–227. [Google Scholar] [CrossRef] [Green Version]
- Paraskevaidis, E.; Athanasiou, A.; Kalliala, I.; Batistatou, A.; Paraskevaidi, M.; Bilirakis, E.; Nasioutziki, M.; Paschopoulos, M.; Lyons, D.; Arbyn, M.; et al. Invasive cervical cancer following treatment of pre-invasive lesions: A potential theory based on a small case series. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021, 264, 56–59. [Google Scholar] [CrossRef] [PubMed]
- Valasoulis, G.; Stasinou, S.M.; Nasioutziki, M.; Athanasiou, A.; Zografou, M.; Spathis, A.; Loufopoulos, A.; Karakitsos, P.; Paraskevaidis, E.; Kyrgiou, M. Expression of HPV-related biomarkers and grade of cervical intraepithelial lesion at treatment. Acta Obstet. Gynecol. Scand. 2014, 93, 194–200. [Google Scholar] [CrossRef] [PubMed]
- Stasinou, S.M.; Valasoulis, G.; Kyrgiou, M.; Malamou-Mitsi, V.; Bilirakis, E.; Pappa, L.; Deligeoroglou, E.; Nasioutziki, M.; Founta, C.; Daponte, A.; et al. Large loop excision of the transformation zone and cervical intraepithelial neoplasia: A 22-year experience. Anticancer. Res. 2012, 32, 4141–4145. [Google Scholar]
- Purandare, N.C.; Trevisan, J.; Patel, I.I.; Gajjar, K.; Mitchell, A.L.; Theophilou, G.; Valasoulis, G.; Martin, M.; von Bunau, G.; Kyrgiou, M.; et al. Exploiting biospectroscopy as a novel screening tool for cervical cancer: Towards a framework to validate its accuracy in a routine clinical setting. Bioanalysis 2013, 5, 2697–2711. [Google Scholar] [CrossRef]
- Pouliakis, A.; Valasoulis, G.; Michail, G.; Salamalekis, E.; Margari, N.; Kottaridi, C.; Spathis, A.; Karakitsou, E.; Gouloumi, A.R.; Leventakou, D.; et al. New Aspects and an Artificial Intelligence Approach for the Detection of Cervical Abnormalities: The COVID-19 Pandemic Era. In Quality of Healthcare in the Aftermath of the COVID-19 Pandemic; Anastasius, M., Ed.; IGI Global: Hershey, PA, USA, 2022; pp. 192–214. [Google Scholar]
- Pouliakis, A.; Karakitsou, E.; Chrelias, C.; Pappas, A.; Panayiotides, I.; Valasoulis, G.; Kyrgiou, M.; Paraskevaidis, E.; Karakitsos, P. The Application of Classification and Regression Trees for the Triage of Women for Referral to Colposcopy and the Estimation of Risk for Cervical Intraepithelial Neoplasia: A Study Based on 1625 Cases with Incomplete Data from Molecular Tests. Biomed Res. Int. 2015, 2015, 914740. [Google Scholar] [CrossRef]
- Valasoulis, G.; Tsoumpou, I.; Founta, C.; Kyrgiou, M.; Dalkalitsis, N.; Nasioutziki, M.; Kassanos, D.; Paraskevaidis, E.; Karakitsos, P. The role of p16(INK4a) immunostaining in the risk assessment of women with LSIL cytology: A prospective pragmatic study. Eur. J. Gynaecol. Oncol. 2011, 32, 150–152. [Google Scholar]
- Lima, K.M.G.; Gajjar, K.; Valasoulis, G.; Nasioutziki, M.; Kyrgiou, M.; Karakitsos, P.; Paraskevaidis, E.; Martin Hirsch, P.L.; Martin, F.L. Classification of cervical cytology for human papilloma virus (HPV) infection using biospectroscopy and variable selection techniques. Anal. Methods 2014, 6, 9643–9652. [Google Scholar] [CrossRef]
- Ronco, G.; Giorgi Rossi, P. Role of HPV DNA testing in modern gynaecological practice. Best Pract. Res. Clin. Obstet. Gynaecol. 2018, 47, 107–118. [Google Scholar] [CrossRef] [PubMed]
- Paraskevaidis, E.; Athanasiou, A.; Paraskevaidi, M.; Bilirakis, E.; Galazios, G.; Kontomanolis, E.; Dinas, K.; Loufopoulos, A.; Nasioutziki, M.; Kalogiannidis, I.; et al. Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study. In Vivo 2020, 34, 1445–1449. [Google Scholar] [CrossRef] [PubMed]
- Valasoulis, G.; Pouliakis, A.; Michail, G.; Kottaridi, C.; Spathis, A.; Kyrgiou, M.; Paraskevaidis, E.; Daponte, A. Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women. Cancers 2020, 12, 1164. [Google Scholar] [CrossRef] [PubMed]
- Kyrgiou, M.; Koliopoulos, G.; Martin-Hirsch, P.; Arbyn, M.; Prendiville, W.; Paraskevaidis, E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 2006, 367, 489–498. [Google Scholar] [CrossRef]
- Arbyn, M.; Kyrgiou, M.; Simoens, C.; Raifu, A.O.; Koliopoulos, G.; Martin-Hirsch, P.; Prendiville, W.; Paraskevaidis, E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Meta-analysis. BMJ 2008, 337, a1284. [Google Scholar] [CrossRef] [Green Version]
- Kyrgiou, M.; Bowden, S.J.; Athanasiou, A.; Paraskevaidi, M.; Kechagias, K.; Zikopoulos, A.; Terzidou, V.; Martin-Hirsch, P.; Arbyn, M.; Bennett, P.; et al. Morbidity after local excision of the transformation zone for cervical intra-epithelial neoplasia and early cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2021, 75, 10–22. [Google Scholar] [CrossRef]
- Noehr, B.; Jensen, A.; Frederiksen, K.; Tabor, A.; Kjaer, S.K. Loop electrosurgical excision of the cervix and risk for spontaneous preterm delivery in twin pregnancies. Obstet. Gynecol. 2009, 114, 511–515. [Google Scholar] [CrossRef]
- Noehr, B.; Jensen, A.; Frederiksen, K.; Tabor, A.; Kjaer, S.K. Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: A population-based study of singleton deliveries during a 9-year period. Am. J. Obstet. Gynecol. 2009, 201, 33.e1–33.e6. [Google Scholar] [CrossRef]
- Ortoft, G.; Henriksen, T.; Hansen, E.; Petersen, L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG Int. J. Obstet. Gynaecol. 2010, 117, 258–267. [Google Scholar] [CrossRef]
- Kyrgiou, M.; Valasoulis, G.; Stasinou, S.M.; Founta, C.; Athanasiou, A.; Bennett, P.; Paraskevadis, E. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. Int. J. Gynaecol. Obstet. 2015, 128, 141–147. [Google Scholar] [CrossRef] [PubMed]
- Kyrgiou, M.; Pouliakis, A.; Panayiotides, J.G.; Margari, N.; Bountris, P.; Valasoulis, G.; Paraskevaidi, M.; Bilirakis, E.; Nasioutziki, M.; Loufopoulos, A.; et al. Personalised management of women with cervical abnormalities using a clinical decision support scoring system. Gynecol. Oncol. 2016, 141, 29–35. [Google Scholar] [CrossRef] [PubMed]
- Manhart, L.E.; Koutsky, L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex. Transm. Dis. 2002, 29, 725–735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Valasoulis, G.; Pouliakis, A.; Michail, G.; Daponte, A.I.; Galazios, G.; Panayiotides, I.G.; Daponte, A. The Influence of Sexual Behavior and Demographic Characteristics in the Expression of HPV-Related Biomarkers in a Colposcopy Population of Reproductive Age Greek Women. Biology 2021, 10, 713. [Google Scholar] [CrossRef]
- Winer, R.L.; Hughes, J.P.; Feng, Q.; O’Reilly, S.; Kiviat, N.B.; Holmes, K.K.; Koutsky, L.A. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 2006, 354, 2645–2654. [Google Scholar] [CrossRef]
- Hogewoning, C.J.; Bleeker, M.C.; van den Brule, A.J.; Voorhorst, F.J.; Snijders, P.J.; Berkhof, J.; Westenend, P.J.; Meijer, C.J. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. Int. J. Cancer 2003, 107, 811–816. [Google Scholar] [CrossRef]
- Valasoulis, G.; Koliopoulos, G.; Founta, C.; Kyrgiou, M.; Tsoumpou, I.; Valari, O.; Martin-Hirsch, P.; Daponte, A.; Karakitsos, P.; Paraskevaidis, E. Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecol. Oncol. 2011, 121, 43–48. [Google Scholar] [CrossRef]
- Eriksen, D.O.; Jensen, P.T.; Schroll, J.B.; Hammer, A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2022, 101, 597–607. [Google Scholar] [CrossRef]
- Henry, M.R. The Bethesda System 2001:An update of new terminology for gynecologic cytology. Clin. Lab. Med. 2003, 23, 585–603. [Google Scholar] [CrossRef]
- Smith, J.H. Bethesda 2001. Cytopathol. Off. J. Br. Soc. Clin. Cytol. 2002, 13, 4–10. [Google Scholar] [CrossRef] [Green Version]
- Pista, A.; Verdasca, N.; Oliveira, A. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J. Med. Virol. 2011, 83, 272–276. [Google Scholar] [CrossRef] [PubMed]
- Koliopoulos, G.; Valasoulis, G.; Zilakou, E. An update review on HPV testing methods for cervical neoplasia. Expert Opin. Med. Diagn. 2009, 3, 123–131. [Google Scholar] [CrossRef] [PubMed]
- Mandal, R.; Ghosh, I.; Banerjee, D.; Mittal, S.; Muwonge, R.; Roy, C.; Panda, C.; Vernekar, M.; Frappart, L.; Basu, P. Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias. Int. J. Gynecol. Pathol. 2020, 39, 384–390. [Google Scholar] [CrossRef] [PubMed]
- Paraskevaidis, E.; Davidson, E.J.; Koliopoulos, G.; Alamanos, Y.; Lolis, E.; Martin-Hirsch, P. Bleeding after loop electrosurgical excision procedure performed in either the follicular or luteal phase of the menstrual cycle: A randomized trial. Obstet. Gynecol. 2002, 99, 997–1000. [Google Scholar] [CrossRef] [PubMed]
- Tamposis, I.; Iordanidis, E.; Tzortzis, L.; Bountris, P.; Haritou, M.; Koutsouris, D.; Pouliakis, A.; Karakitsos, P. HPVGuard: A software platform to support management and prognosis of cervical cancer. In Proceedings of the 2014 4th International Conference on Wireless Mobile Communication and Healthcare-Transforming Healthcare Through Innovations in Mobile and Wireless Technologies (MOBIHEALTH), Athens, Greece, 3–5 November 2014; pp. 401–405. [Google Scholar]
- Rebolj, M.; Helmerhorst, T.; Habbema, D.; Looman, C.; Boer, R.; van Rosmalen, J.; van Ballegooijen, M. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: Population based cohort study. BMJ 2012, 345, e6855. [Google Scholar] [CrossRef] [Green Version]
- Andersson, S.; Megyessi, D.; Belkić, K.; Alder, S.; Östensson, E.; Mints, M. Age, margin status, high-risk human papillomavirus and cytology independently predict recurrent high-grade cervical intraepithelial neoplasia up to 6 years after treatment. Oncol. Lett. 2021, 22, 684. [Google Scholar] [CrossRef]
- Valari, O.; Koliopoulos, G.; Karakitsos, P.; Valasoulis, G.; Founta, C.; Godevenos, D.; Dova, L.; Paschopoulos, M.; Loufopoulos, A.; Paraskevaidis, E. Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: Predictors and clinical implications. Gynecol. Oncol. 2011, 122, 505–508. [Google Scholar] [CrossRef]
- Rabasa, J.; Alcalde, A.; Bradbury, M.; Sánchez-Iglesias, J.L.; Guerrero, D.; Forcada, C.; Pérez-Benavente, A.; Cabrera, S.; Ramón, Y.C.S.; Hernández, J.; et al. Intraoperative Human Papillomavirus Test Predicts 24-Month High-Grade Squamous Intraepithelial Lesion Recurrence Saving Costs: A Prospective Cohort Study. J. Low. Genit. Tract Dis. 2020, 24, 367–371. [Google Scholar] [CrossRef]
- Vaccarella, S.; Franceschi, S.; Herrero, R.; Muñoz, N.; Snijders, P.J.; Clifford, G.M.; Smith, J.S.; Lazcano-Ponce, E.; Sukvirach, S.; Shin, H.R.; et al. Sexual behavior, condom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol. Biomark. Prev. 2006, 15, 326–333. [Google Scholar] [CrossRef] [Green Version]
- de Sanjose, S.; Almirall, R.; Lloveras, B.; Font, R.; Diaz, M.; Muñoz, N.; Català, I.; Meijer, C.J.; Snijders, P.J.; Herrero, R.; et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex. Transm. Dis. 2003, 30, 788–793. [Google Scholar] [CrossRef]
- Lam, J.U.; Rebolj, M.; Dugué, P.A.; Bonde, J.; von Euler-Chelpin, M.; Lynge, E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: Systematic review of longitudinal studies. J. Med. Screen. 2014, 21, 38–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Innamaa, A.; Dudding, N.; Ellis, K.; Crossley, J.; Smith, J.H.; Tidy, J.A.; Palmer, J.E. High-risk HPV platforms and test of cure: Should specific HPV platforms more suited to screening in a ‘test of cure’ scenario be recommended? Cytopathology 2015, 26, 381–387. [Google Scholar] [CrossRef] [Green Version]
- Cuschieri, K.; Bhatia, R.; Cruickshank, M.; Hillemanns, P.; Arbyn, M. HPV testing in the context of post-treatment follow up (test of cure). J. Clin. Virol. 2016, 76 (Suppl. 1), S56–S61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zappacosta, R.; Ianieri, M.M.; Tinelli, A.; Gustapane, S.; D’Angelo, C.; Gatta, D.M.; Capanna, S.; Rosini, S. Detection of residual/recurrent cervical disease after successful LEEP conization: The possible role of mRNA-HPV test. Curr. Pharm. Des. 2013, 19, 1450–1457. [Google Scholar] [PubMed]
- Tisi, G.; Gargiulo, F.; Gozzini, E.; Baronchelli, C.; Odicino, F.; Salinaro, F.; Sartori, E.; Caruso, A.; Facchetti, F.; De Francesco, M.A. Role of HPV DNA, HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. Apmis 2019, 127, 196–201. [Google Scholar] [CrossRef]
- Parthenis, C.; Panagopoulos, P.; Margari, N.; Kottaridi, C.; Spathis, A.; Pouliakis, A.; Konstantoudakis, S.; Chrelias, G.; Chrelias, C.; Papantoniou, N.; et al. The association between sexually transmitted infections, human papillomavirus, and cervical cytology abnormalities among women in Greece. Int. J. Infect. Dis. 2018, 73, 72–77. [Google Scholar] [CrossRef]
- Mitra, A.; MacIntyre, D.A.; Paraskevaidi, M.; Moscicki, A.B.; Mahajan, V.; Smith, A.; Lee, Y.S.; Lyons, D.; Paraskevaidis, E.; Marchesi, J.R.; et al. The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia. Genome. Med. 2021, 13, 176. [Google Scholar] [CrossRef]
- Tsakiroglou, M.; Bakalis, M.; Valasoulis, G.; Paschopoulos, M.; Koliopoulos, G.; Paraskevaidis, E. Women’s knowledge and utilization of gynecological cancer prevention services in the Northwest of Greece. Eur. J. Gynaecol. Oncol. 2011, 32, 178–181. [Google Scholar]
- Gravitt, P.E.; Winer, R.L. Natural History of HPV Infection across the Lifespan: Role of Viral Latency. Viruses 2017, 9, 267. [Google Scholar] [CrossRef]
- Gravitt, P.; Winer, R. Latency or New Infection? Evidence-Based Counseling in the Era of HPV-Based Screening. 2018. Available online: http://www.HPVWorld.com (accessed on 11 June 2022).
- Wheeler, C.M.; Skinner, S.R.; Del Rosario-Raymundo, M.R.; Garland, S.M.; Chatterjee, A.; Lazcano-Ponce, E.; Salmerón, J.; McNeil, S.; Stapleton, J.T.; Bouchard, C.; et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016, 16, 1154–1168. [Google Scholar] [CrossRef]
- Daponte, A.; Michail, G.; Daponte, A.I.; Daponte, N.; Valasoulis, G. Urine HPV in the Context of Genital and Cervical Cancer Screening-An Update of Current Literature. Cancers 2021, 13, 1640. [Google Scholar] [CrossRef] [PubMed]
Consistent Use (≥90%) (N = 70) | Inconsistent Use (<90%) (N = 134) | p | |
---|---|---|---|
Age (Median, Q1–Q3) | 37.5 (33–43) | 38 (34–41) | 0.8995 |
Number of children (Median, Q1–Q3) | 1 (0–2) | 1 (0–2) | 0.2803 |
Age of sexual activity initiation (Median, Q1–Q3) | 19 (18–20) | 19 (17–20) | 0.5665 |
Number of sex partners (Median, Q1–Q3) | 3 (2–5) | 3 (2–5) | 0.7960 |
Smoking in packet years (Median, Q1–Q3) | 2 (0–10) | 3 (0–10) | 0.8719 |
Parity (N, %) | 45 (64.3%) | 92 (68.7%) | 0.5280 |
Delivery via CS (N, %) | 16 (35.6%) | 37 (40.2) | 0.5988 |
Referral cytology | 0.1448 | ||
NILM | 0 (0%) | 1 (0.75%) | |
HPV | 6 (8.57%) | 15 (11.19%) | |
LGSIL | 28 (40%) | 31 (23.13%) | |
ASC-US | 5 (7.14%) | 14 (10.45%) | |
ASC-H | 0 (0%) | 6 (4.48%) | |
AGC | 1 (1.43%) | 3 (2.24%) | |
HGSIL | 30 (42.86%) | 64 (47.76%) | |
Colposcopy on study entry (N, %) | 0.6189 | ||
Negative | 0 (0%) | 1 (0.75%) | |
HPV | 4 (5.71%) | 6 (4.48%) | |
LGSIL | 30 (42.86%) | 47 (35.07%) | |
HGSIL | 36 (51.43%) | 80 (59.7%) |
Histology | Cumulative HR HPV DNA Positivity | |||||
---|---|---|---|---|---|---|
Colposcopic Impression | No CIN evidence | CIN-1 | CIN-2 | CIN-3 | Micro invasion | |
Negative | - | - | 1 (100%) | - | - | 1 (100%) |
HPV | - | 9 (78%) | 1 (100%) | - | - | 10 (80%) |
LGSIL | - | 63 (43%) | 13 (92%) | 1 (100%) | - | 77 (52%) |
HGSIL | - | 9 (56%) | 42 (90%) | 63 (98%) | 2 (100%) | 116 (92%) |
Total | - | 81 (48%) | 57 (91%) | 64 (98%) | 2 (100%) | 204 (76%) |
Consistent Use (≥90%) (N = 70) | Inconsistent Use (<90%) (N = 134) | |||||||
---|---|---|---|---|---|---|---|---|
Consistent (N) | Inconsistent (N) | Positives | Negatives | Positives | Negatives | p | OR (95% CI) | |
HPV DNA test results | 70 | 134 | 61 (87.1%) | 9 (12.9%) | 114 (85.1%) | 20 (14.9%) | 0.6880 | 1.2 (0.5–2.8) |
NASBA results | 64 | 130 | 29 (45.3%) | 35 (54.7%) | 64 (49.2%) | 66 (50.8%) | 0.6075 | 0.85 (0.47–1.6) |
Flow cytometry results | 70 | 133 | 40 (57.1%) | 30 (42.9%) | 72 (54.1%) | 61 (45.9%) | 0.6821 | 1.1 (0.6–2.0) |
p16 results | 67 | 132 | 22 (32.8%) | 45 (67.2%) | 41 (31.1%) | 91 (68.9%) | 0.7992 | 1.1 (0.6–2.0) |
Consistent Use (≥90%) (N = 70) | Inconsistent Use (<90%) (N = 134) | |||||||
---|---|---|---|---|---|---|---|---|
Consistent (N) | Inconsistent (N) | Positives | Negatives | Positives | Negatives | p | OR/RR (95% CI) | |
HPV DNA test results | 69 | 134 | 16 (23.2%) | 53 (76.8%) | 83 (61.9%) | 51 (38.1%) | <0.0001 | 0.19 (0.10–0.36) |
NASBA results | 62 | 125 | 1 (1.6%) | 61 (98.4%) | 10 (8%) | 115 (92%) | 0.1039 | 0.19 (0.02–1.51) |
Flow cytometry results | 70 | 128 | 5 (7.1%) | 65 (92.9%) | 21 (16.4%) | 107 (83.6%) | 0.0791 | 0.39 (0.14–1.09) |
p16 results | 67 | 125 | 0 (0%) | 67 (100%) | 6 (4.8%) | 119 (95.2%) | 0.0983 | RR: 0.64 (0.57–0.71) |
Consistent Use (≥90%) (N = 70) | Inconsistent Use (<90%) (N = 134) | |||||||
---|---|---|---|---|---|---|---|---|
Consistent (N) | Inconsistent (N) | Positives | Negatives | Positives | Negatives | p | OR (95% CI) | |
HPV DNA test results | 69 | 134 | 9 (13%) | 60 (87%) | 95 (70.9%) | 39 (29.1%) | <0.0001 | 0.06 (0.03–0.13) |
NASBA results | 63 | 129 | 4 (6.3%) | 59 (93.7%) | 23 (17.8%) | 106 (82.2%) | 0.0448 | 0.31 (0.10–0.95) |
Flow cytometry results | 70 | 131 | 7 (10%) | 63 (90%) | 24 (18.3%) | 107 (81.7%) | 0.1521 | 0.50 (0.20–1.22) |
p16 results | 63 | 121 | 1 (1.6%) | 62 (98.4%) | 6 (5%) | 115 (95%) | 0.1686 | 0.23 (0.03–1.86) |
Description | Treatment Failures (N = 10) | Successful Treatments (N = 194) | p | OR/RR and 95% CI |
---|---|---|---|---|
HPV DNA test results at enrollment (positive) | 10/100% | 165/85.05% | 0.3631 | RR: 0.85 (0.80–0.90) |
HPV DNA test results at 6 months (positive) | 7/70% | 92/47.67% | 0.2054 | 2.56 (0.64–10.2) |
HPV DNA test results at 24 months (positive) | 10/100% | 94/48.7% | 0.0016 | RR: 0.49 (0.42–0.56) |
HPV mRNA test results at enrollment (positive) | 6/60% | 87/47.28% | 0.5244 | 1.67 (0.46–6.12) |
HPV mRNA test results at 6 months (positive) | 4/40% | 7/3.96% | 0.0012 | 16.19 (3.71–70.68) |
HPV mRNA test results at 24 months (positive) | 8/80% | 19/10.44% | <0.0001 | 34.32 (6.79–173.52) |
Flow cytometry at enrollment (positive) | 7/70% | 105/54.4% | 0.5168 | 1.96 (0.49–7.79) |
Flow cytometry at 6 months (positive) | 3/30% | 23/12.23% | 0.1288 | 3.07 (0.74–12.73) |
Flow cytometry at 24 months (positive) | 6/60% | 25/13.09% | 0.0011 | 9.96 (2.63–37.78) |
p16 at enrollment (positive) | 7/70% | 56/29.63% | 0.0125 | 5.54 (1.38–22.21) |
p16 at 6 months (positive) | 3/30% | 4/2.2% | 0.0032 | 19.07 (3.57–101.99) |
p16 at 24 months (positive) | 6/60% | 3/1.72% | <0.0001 | 85.5 (15.56–469.89) |
Condom use (compliant >90%) | 1/10% | 69/35.57% | 0.1693 | 0.2 (0.03–1.62) |
Parity (Yes) | 9/90% | 128/65.98% | 0.1707 | 4.64 (0.58–37.42) |
Mode of delivery (VD) | 6/66.7% | 78/60.94% | 1.0000 | 1.28 (0.31–5.36) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Valasoulis, G.; Michail, G.; Pouliakis, A.; Androutsopoulos, G.; Panayiotides, I.G.; Kyrgiou, M.; Daponte, A.; Paraskevaidis, E. Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study. Cancers 2022, 14, 3530. https://doi.org/10.3390/cancers14143530
Valasoulis G, Michail G, Pouliakis A, Androutsopoulos G, Panayiotides IG, Kyrgiou M, Daponte A, Paraskevaidis E. Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study. Cancers. 2022; 14(14):3530. https://doi.org/10.3390/cancers14143530
Chicago/Turabian StyleValasoulis, George, Georgios Michail, Abraham Pouliakis, Georgios Androutsopoulos, Ioannis. G. Panayiotides, Maria Kyrgiou, Alexandros Daponte, and Evangelos Paraskevaidis. 2022. "Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study" Cancers 14, no. 14: 3530. https://doi.org/10.3390/cancers14143530